查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1982807

全球自体细胞疗法市场规模、份额、趋势和成长分析报告（2026-2034年）

Global Autologous Cell Therapy Market Size, Share, Trends & Growth Analysis Report 2026-2034
出版日期: | 出版商: Value Market Research | 英文 114 Pages | 商品交期: 最快1-2个工作天内

价格
简介目录

自体细胞疗法市场预计将从 2025 年的 73.1 亿美元成长到 2034 年的 453.6 亿美元，2026 年至 2034 年的复合年增长率为 22.48%。

随着个人化医疗的发展，全球自体细胞疗法市场备受关注。自体细胞疗法利用患者自身的细胞进行治疗，进而降低免疫排斥的风险，并提高治疗的适用性。这种方法正越来越多地应用于再生医学和某些癌症治疗领域。

自体细胞疗法市场的成长受到多种因素的推动。慢性疾病盛行率的上升以及人们对再生医学日益增长的兴趣，正在促进细胞疗法的研究和开发。此外，生物技术和细胞处理技术的进步也提高了这些疗法的疗效。

随着临床研究的不断深入，自体细胞疗法市场预计将持续成长。细胞分离、处理和储存技术的进步有望带来更佳的治疗效果。此外，对再生医学和个人化医疗领域投资的增加，预计也将推动市场的长期发展。

目录

第一章：引言

第二章执行摘要

第三章 市场变数、趋势与框架

  • 市场谱系展望
  • 渗透率和成长前景分析
  • 价值链分析
  • 法律规范
    • 标准与合规性
    • 监管影响分析
  • 市场动态
    • 市场驱动因素
    • 市场限制因素
    • 市场机会
    • 市场挑战
  • 波特五力分析
  • PESTLE分析

第四章：全球自体细胞疗法市场：依治疗方法划分

  • 市场分析、洞察与预测
  • 干细胞疗法
  • 非干细胞疗法

第五章 全球自体细胞疗法市场：依治疗领域划分

  • 市场分析、洞察与预测
  • 肿瘤学
  • 心血管疾病（CVD）
  • 肌肉骨骼疾病
  • 皮肤科
  • 其他的

第六章 全球自体细胞疗法市场：依地区划分

  • 区域分析
  • 北美市场分析、洞察与预测
    • 我们
    • 加拿大
    • 墨西哥
  • 欧洲市场分析、洞察与预测
    • 英国
    • 法国
    • 德国
    • 义大利
    • 俄罗斯
    • 其他欧洲国家
  • 亚太市场分析、洞察与预测
    • 印度
    • 日本
    • 韩国
    • 澳洲
    • 东南亚
    • 其他亚太国家
  • 拉丁美洲市场分析、洞察与预测
    • 巴西
    • 阿根廷
    • 秘鲁
    • 智利
    • 其他拉丁美洲国家
  • 中东和非洲市场分析、洞察与预测
    • 沙乌地阿拉伯
    • UAE
    • 以色列
    • 南非
    • 其他中东和非洲国家

第七章 竞争情势

  • 最新趋势
  • 公司分类
  • 供应链和销售管道合作伙伴（根据现有资讯）
  • 市场占有率和市场定位分析（基于现有资讯）
  • 供应商情况（基于现有资讯）
  • 策略规划

第八章：公司简介

  • 主要公司的市占率分析
  • 公司简介
    • Bluebird Bio Inc
    • Novartis
    • Gilead Sciences Inc.（Kite）
    • Bristol-Myers Squibb Company
    • Pharmicell Co. Ltd
    • Johnson & Johnson（Janssen Global Services LLC.）
    • JW Therapeutics
    • Holostem SRL
    • Vertex Pharmaceuticals Inc
    • Autolus Therapeutics
简介目录
Product Code: VMR11212590

The Autologous Cell Therapy Market size is expected to reach USD 45.36 Billion in 2034 from USD 7.31 Billion (2025) growing at a CAGR of 22.48% during 2026-2034.

The global autologous cell therapy market has gained significant attention as personalized medicine continues to advance. Autologous cell therapy involves using a patient's own cells for treatment, reducing the risk of immune rejection and improving treatment compatibility. This approach is increasingly used in regenerative medicine and certain cancer therapies.

Several factors are driving the growth of the autologous cell therapy market. Rising prevalence of chronic diseases and increasing interest in regenerative treatments have encouraged research and development in cell-based therapies. Additionally, advancements in biotechnology and cell processing technologies have improved the effectiveness of these therapies.

Looking ahead, the autologous cell therapy market is expected to grow as clinical research continues to expand. Improvements in cell isolation, processing, and storage techniques may enhance treatment outcomes. Furthermore, increasing investments in regenerative medicine and personalized healthcare will likely support long-term market development.

Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:

Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.

Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.

Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.

Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.

Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.

Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.

Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.

MARKET SEGMENTATION

By Therapy Type

  • Stem Cell Therapies
  • Non-Stem Cell Therapies

By Therapeutic Area

  • Oncology
  • Cardiovascular Disease (CVD)
  • Musculoskeletal Disorders
  • Dermatology
  • Others

COMPANIES PROFILED

  • Bluebird bio Inc, Novartis, Gilead Sciences Inc Kite, BristolMyers Squibb Company, Pharmicell Co Ltd, Johnson Johnson Janssen Global Services LLC, JW Therapeutics, Holostem Srl, Vertex Pharmaceuticals Inc, Autolus therapeutics
  • We can customise the report as per your requirements.

TABLE OF CONTENTS

Chapter 1. PREFACE

  • 1.1. Market Segmentation & Scope
  • 1.2. Market Definition
  • 1.3. Information Procurement
    • 1.3.1 Information Analysis
    • 1.3.2 Market Formulation & Data Visualization
    • 1.3.3 Data Validation & Publishing
  • 1.4. Research Scope and Assumptions
    • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

  • 2.1. Market Snapshot
  • 2.2. Segmental Outlook
  • 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

  • 3.1. Market Lineage Outlook
  • 3.2. Penetration & Growth Prospect Mapping
  • 3.3. Value Chain Analysis
  • 3.4. Regulatory Framework
    • 3.4.1 Standards & Compliance
    • 3.4.2 Regulatory Impact Analysis
  • 3.5. Market Dynamics
    • 3.5.1 Market Drivers
    • 3.5.2 Market Restraints
    • 3.5.3 Market Opportunities
    • 3.5.4 Market Challenges
  • 3.6. Porter's Five Forces Analysis
  • 3.7. PESTLE Analysis

Chapter 4. GLOBAL AUTOLOGOUS CELL THERAPY MARKET: BY THERAPY TYPE 2022-2034 (USD MN)

  • 4.1. Market Analysis, Insights and Forecast Therapy Type
  • 4.2. Stem Cell Therapies Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 4.3. Non-Stem Cell Therapies Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL AUTOLOGOUS CELL THERAPY MARKET: BY THERAPEUTIC AREA 2022-2034 (USD MN)

  • 5.1. Market Analysis, Insights and Forecast Therapeutic Area
  • 5.2. Oncology Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 5.3. Cardiovascular Disease (CVD) Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 5.4. Musculoskeletal Disorders Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 5.5. Dermatology Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 5.6. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL AUTOLOGOUS CELL THERAPY MARKET: BY REGION 2022-2034(USD MN)

  • 6.1. Regional Outlook
  • 6.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 6.2.1 By Therapy Type
    • 6.2.2 By Therapeutic Area
    • 6.2.3 United States
    • 6.2.4 Canada
    • 6.2.5 Mexico
  • 6.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 6.3.1 By Therapy Type
    • 6.3.2 By Therapeutic Area
    • 6.3.3 United Kingdom
    • 6.3.4 France
    • 6.3.5 Germany
    • 6.3.6 Italy
    • 6.3.7 Russia
    • 6.3.8 Rest Of Europe
  • 6.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 6.4.1 By Therapy Type
    • 6.4.2 By Therapeutic Area
    • 6.4.3 India
    • 6.4.4 Japan
    • 6.4.5 South Korea
    • 6.4.6 Australia
    • 6.4.7 South East Asia
    • 6.4.8 Rest Of Asia Pacific
  • 6.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 6.5.1 By Therapy Type
    • 6.5.2 By Therapeutic Area
    • 6.5.3 Brazil
    • 6.5.4 Argentina
    • 6.5.5 Peru
    • 6.5.6 Chile
    • 6.5.7 South East Asia
    • 6.5.8 Rest of Latin America
  • 6.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 6.6.1 By Therapy Type
    • 6.6.2 By Therapeutic Area
    • 6.6.3 Saudi Arabia
    • 6.6.4 UAE
    • 6.6.5 Israel
    • 6.6.6 South Africa
    • 6.6.7 Rest of the Middle East And Africa

Chapter 7. COMPETITIVE LANDSCAPE

  • 7.1. Recent Developments
  • 7.2. Company Categorization
  • 7.3. Supply Chain & Channel Partners (based on availability)
  • 7.4. Market Share & Positioning Analysis (based on availability)
  • 7.5. Vendor Landscape (based on availability)
  • 7.6. Strategy Mapping

Chapter 8. COMPANY PROFILES OF GLOBAL AUTOLOGOUS CELL THERAPY INDUSTRY

  • 8.1. Top Companies Market Share Analysis
  • 8.2. Company Profiles
    • 8.2.1 Bluebird Bio Inc
    • 8.2.2 Novartis
    • 8.2.3 Gilead Sciences Inc. (Kite)
    • 8.2.4 Bristol-Myers Squibb Company
    • 8.2.5 Pharmicell Co. Ltd
    • 8.2.6 Johnson & Johnson (Janssen Global Services LLC.)
    • 8.2.7 JW Therapeutics
    • 8.2.8 Holostem S.R.L
    • 8.2.9 Vertex Pharmaceuticals Inc
    • 8.2.10 Autolus Therapeutics